Study guide

11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

Key Takeaways Explain This Topic AI

Integrase inhibitors chelate polyvalent cations, so separate them from calcium, iron and antacids (before by 2 hours or after by 6) unless the monograph allows co-administration with food.

HIV PEP starts as soon as possible within 72 hours and lasts 28 days; PrEP with TDF/emtricitabine needs HIV, renal, hepatitis B and STI testing every 3 months.

Screen for hepatitis B before rituximab, other potent immunosuppressants and hepatitis C antivirals because of the risk of HBV reactivation.

Canadian first-line treatment for TB infection is 4 months of rifampin or 12 weekly doses of rifapentine plus isoniazid, after active TB is ruled out.

Rifampin is a potent enzyme inducer, and fluconazole raises warfarin effect even after a single 150 mg dose.

Last updated: October 2026

HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

These infections share three exam themes: prevention (PrEP, PEP, vaccination, latent TB treatment), drug interactions (boosters, rifamycins, azoles, polyvalent cations), and adherence and monitoring over long courses. Community pharmacists dispense most of these therapies and often catch the interactions first.

1. HIV Treatment Principles

Start antiretroviral therapy (ART) for everyone with HIV, as soon as possible. A durably undetectable viral load prevents sexual transmission ("Undetectable = Untransmittable").

Usual initial regimens combine an integrase strand transfer inhibitor (INSTI) with two nucleoside reverse transcriptase inhibitors. Examples: bictegravir/emtricitabine/tenofovir alafenamide (one tablet daily), or dolutegravir plus two NRTIs. Dolutegravir/lamivudine is an option for selected patients without hepatitis B.

HLA-B*5701 testing is required before abacavir, because carriers are at high risk of a hypersensitivity reaction. Never rechallenge after a suspected reaction.

Tenofovir: tenofovir disoproxil fumarate (TDF) carries more renal and bone toxicity than tenofovir alafenamide (TAF). Monitor creatinine and urine protein.

High-Yield ART Interactions

Interaction Mechanism Management

INSTIs + polyvalent cations (calcium, iron, magnesium, aluminum, zinc, antacids, multivitamins) Chelation in the gut lowers INSTI absorption Take dolutegravir or bictegravir 2 hours before or 6 hours after cation products. With food, iron or calcium may be taken at the same time as dolutegravir (follow the monograph)

Boosters (ritonavir, cobicistat) + CYP3A4 substrates Strong CYP3A4 inhibition Avoid simvastatin and lovastatin; reduce doses of others. Inhaled or intranasal fluticasone and budesonide can cause Cushing's syndrome . Midazolam, some antiarrhythmics and ergots are contraindicated

Rifampin + most ART Strong induction lowers ART levels Use rifabutin with dose changes, or adjust the INSTI dose (dolutegravir twice daily) under specialist direction

  • Dolutegravir + metformin Dolutegravir raises metformin levels Limit the metformin dose and monitor
  • 2. HIV Pre- and Post-Exposure Prophylaxis

PrEP (pre-exposure prophylaxis):

Regimen: TDF/emtricitabine once daily. For men who have sex with men, "on-demand" (2-1-1) dosing is an alternative: two tablets 2 to 24 hours before sex, then one tablet 24 and 48 hours after the first dose.

Before starting: a negative HIV test, creatinine, hepatitis B status (stopping TDF/FTC can trigger an HBV flare), STI screening and pregnancy testing.

Follow-up: repeat HIV and STI testing every 3 months .

PEP (post-exposure prophylaxis):

Timing: start as soon as possible, ideally within 2 hours and no later than 72 hours after a high-risk exposure.

Regimen: a 3-drug course for 28 days (for example, bictegravir/FTC/TAF, or TDF/FTC plus dolutegravir or raltegravir).

Follow-up: baseline and follow-up HIV testing. Check hepatitis B and C status and tetanus need after needlestick injuries.

3. Viral Hepatitis

Hepatitis A: inactivated vaccine for travellers, people with chronic liver disease, men who have sex with men, and people who use drugs.

Hepatitis B:

Vaccination: routine childhood vaccination, plus at-risk adults (3-dose series; a 2-dose adjuvanted adult vaccine also exists).

Chronic HBV: treated with tenofovir (TDF or TAF) or entecavir . Treatment is usually long-term. Stopping abruptly can cause a severe hepatitis flare.

Reactivation risk: screen for HBV before rituximab , other potent immunosuppressants, chemotherapy, and hepatitis C direct-acting antivirals , all of which can reactivate HBV.

Hepatitis C: curable in more than 95% of patients with pangenotypic direct-acting antivirals (DAAs):

Sofosbuvir/velpatasvir for 12 weeks.

Glecaprevir/pibrentasvir for 8 weeks in most treatment-naive patients without decompensated cirrhosis.

Interaction red flags: amiodarone with sofosbuvir can cause severe bradycardia. Acid suppressants reduce velpatasvir absorption, so PPIs need specific timing or are avoided. Rifampin, carbamazepine and St. John's wort reduce DAA levels. Glecaprevir/pibrentasvir is not used with ethinyl estradiol-containing products (ALT elevations).

Cure is confirmed by an undetectable HCV RNA 12 weeks after therapy (SVR12). Reinfection is possible, so harm-reduction counselling continues.

  • 4. Tuberculosis
  • TB Infection (Latent TB) — Canadian Tuberculosis Standards, 8th Edition

First-line: 3HP (once-weekly rifapentine plus isoniazid for 12 doses) or 4R (daily rifampin for 4 months).

Alternatives: if rifamycins cannot be used, 9H (daily isoniazid for 9 months) is preferred, and 6H if 9H is not possible.

Rifapentine is not marketed in Canada. Practitioners obtain it through federal urgent public health need provisions or the Special Access Program.

Rule out active TB before treating TB infection, using symptoms and a chest X-ray.

Active TB

Regimen: standard drug-susceptible therapy is isoniazid, rifampin, pyrazinamide and ethambutol for 2 months, then isoniazid and rifampin for 4 months, preferably as directly observed therapy.

Isoniazid: hepatotoxicity and peripheral neuropathy. Give pyridoxine (vitamin B6) to patients at risk (diabetes, alcohol use, malnutrition, pregnancy, HIV, CKD).

Rifampin: orange-red body fluids (stains soft contact lenses) and strong CYP3A4, CYP2C9 and P-gp induction . It lowers the levels of hormonal contraceptives, warfarin, DOACs, methadone, azoles, many antiretrovirals and immunosuppressants, so check every interaction.

Ethambutol: optic neuritis, so check visual acuity and colour vision.

5. Fungal Infections

Infection Treatment Key counselling

Vulvovaginal candidiasis Fluconazole 150 mg once orally (Schedule III), or a topical azole for 1 to 7 days Pregnancy: topical azole for 7 days , not oral fluconazole. Refer if recurrent (4 or more episodes a year), first episode, or symptoms suggest another cause

Oral thrush Nystatin suspension (swish and swallow), or fluconazole for moderate disease Rinse after inhaled corticosteroids; check dentures

Tinea pedis and corporis Topical terbinafine (1 to 2 weeks) or azoles (2 to 4 weeks) Continue for 1 to 2 weeks after the skin clears; keep feet dry

Onychomycosis Oral terbinafine 250 mg daily for 6 weeks (fingernails) or 12 weeks (toenails); topical efinaconazole for mild disease Confirm the diagnosis first; baseline liver tests; full nail regrowth takes 12 to 18 months

Caution

Azole interactions: fluconazole inhibits CYP2C9 and CYP3A4 and markedly raises warfarin INR, even after a single 150 mg dose. It also increases sulfonylurea and phenytoin levels. Itraconazole and ketoconazole are strong CYP3A4 inhibitors.